Antimicrobial Stewardship

A Centers for Disease Control and Prevention study looked at the COVID-19 pandemic's effect on hospital-onset infections. Study lead author Hannah Wolford offers insights on it, including what patient populations were most affected, and the significance of infection prevention strategies.

Global study reveals sharp rise in deaths linked to high-risk antibiotic use, prompting urgent calls for stewardship reform and surveillance improvements globally.

In a phase 3 study, GSK’s gepotidacin demonstrated 92% efficacy against the sexually transmitted infection.

A surge in invasive group A Streptococcal (IGAS) infections in children marked by more virulent strains followed a reduction in cases coinciding with protective measures for the pandemic.

Study shows benefit using antibiotic earlier in clinical care for gram-negative infections.

Although the TB pipeline has several new agents in various phases, challenges to antimicrobial development remain. Therefore treatment adherence remains paramount.

Key updates from the Centers for Disease Control and Prevention on influenza activity, hospitalizations, pediatric deaths, and current trends across the United States.

Patients with suspected sepsis in the emergency department are twice as likely to survive at 28 days when antibiotics are started within 1 hour.

Indwelling devices and previous antibiotic exposure increased the risk for these infections.

The Visby Medical Women’s Sexual Health Test can screen for chlamydia, gonorrhea, and trichomoniasis.

This is the first in a new class of oral antibiotics for uncomplicated urinary tract infections (uUTIs) in nearly 30 years.

Whitney Hartlage, PharmD, explores the role of expanded UTI definitions and urinalysis interpretation in addressing antibiotic overuse.

A long-term study conducted by the Centers for Disease Control and Prevention (CDC) shows early success in the reduction of such infections followed by an increase again during the early pandemic years. Additionally, certain pathogens overall saw an increase, whereas other infections were stable or saw decreases.

The latest Bench to Bedside column reviews new guidance on the treatment of drug-susceptible and drug-resistance Mycobacterium tuberculosis infections.

A machine learning assessment agrees with an evaluation based on factors identified by infectious diseases experts that IDSA guidelines for treating uncomplicated UTI, last issued in 2011, remain valid today.

This week, phage and antibiotic treatment for resistant Pseudomonas infections, concerns over SEP-1’s impact on sepsis management, and ongoing measles outbreak signaling declining vaccination rates.

A spokesperson from the UK Health Security Agency highlighted key updates in the 2024 UK-AWaRe classification, aligning them with national AMR goals.

Todd Riccobene, PhD, senior scientific director, Anti-Infectives and Infectious Diseases, US Medical Affairs + Health Impact at AbbVie provides more information on the newly approved antibiotic combination for these infections.

Jaime Garcia-Iglesias, PhD discusses community involvement, holistic benefits, and strategies for equitable rollout of doxycycline post-exposure prophylaxis.

Here are some strategies to consider for optimal utilization.

Sean Ong discusses how persistent fever beyond 72 hours emerges as a stronger predictor of mortality in MRSA bacteremia compared to CRP and WBC counts.

The company’s investigational gel, RECCE 327, met primary and secondary endpoints, and it plans to progress to a phase 3 trial.

The trial is being conducted by LimmaTech Biologics, and the first participants have been vaccinated.

An inoculum effect in methicillin-susceptible S aureus infective endocarditis is suspected factor in higher all-cause 30-day mortality with cephazolin treatment than with oxacillin.

A decreasing number of researchers and open positions for infectious disease clinicians and limited residency matches are underlying issues that should be addressed to meet the needs around antimicrobial development and clinical care. Amesh Adalja, MD, FIDSA, discusses some of the challenges behind it.

Hannah Pye, PhD and Evelien Adriaenssens, PhD explore the potential of phages in combating antimicrobial resistance and advancing health across human, animal, and environmental domains.

Carole Mitnick, ScD discusses the impact of the endTB trial's findings on future TB treatment options, including shorter treatment durations, lower costs, and expanded accessibility.

Carole Mitnick, ScD highlights the importance of trust in the success of the endTB trial and addresses the ongoing toxicity concerns with new shorter treatment regimens.

This week, a study on children with invasive candidiasis showed that switching treatment was just as effective, AI is being explored as a tool to combat AMR, and more.